亚胺培南联合西司他丁钠治疗重症肺炎疗效分析.docVIP

亚胺培南联合西司他丁钠治疗重症肺炎的疗效分析 　　[摘要] 目的 探讨对重症肺炎患者采用亚胺培南+西司他丁钠完成治疗后，观察获得的临床疗效。方法 方便选择该院2015年7月―2017年3月收治的164例重症肺炎患者作为实验对象；凭借数字奇偶法对该次研究收治的重症肺炎患者分组；对照组：重症肺炎疾病治疗过程中应用万古霉素药物；观察组：重症肺炎疾病治疗过程中应用亚胺培南+西司他丁钠；对重症肺炎患者病情治疗总有效率差异以及治疗时间指标差异回顾性分析。 结果 观察组重症肺炎患者病情治疗总有效率（98.78%）同对照组重症肺炎患者（84.15%）比较，差异有统计学意义（P0.05）。结论 对于重症肺炎患者，治疗期间采用亚胺培南+西司他丁钠药物联合治疗，对于重症肺炎病情治疗总有效率提高以及治疗时间指标的改善可以做出充分保证，从而优化重症肺炎病情疗效，优化其生活质量。 　　[关键词] 亚胺培南；西司他丁钠；重症肺炎 　　[中图分类号] R563.1 [文献标识码] A [文章编号] 1674-0742（2017）09（b）-0115-03 　　[Abstract] Objective This paper tries to investigate the patients with severe pneumonia with imipenem and cilastatin sodium and to observe the clinical curative effect. Methods 164 cases of patients with severe pneumonia in this hospital from July 2015 to March 2017 were convenient selected as experimental objects and divided into the control group and the observation group with digital method of parity； the control group adopted the application of vancomycin in the treatment of severe pneumonia disease； the observation group adopted application of imipenem and cilastatin sodium in the treatment of severe pneumonia disease； the efficiency differences and treatment time index on patients with severe pneumonia were retrospectively analyzed. Results The total efficiency of the observation group was 98.78%， and the control group of patients with severe pneumonia was 84.15%， the difference was significantly significlent（P0.05）. Conclusion For patients with severe pneumonia， during treatment， the combined drug therapy of imipenem and cilastatin sodium for severe pneumonia is remarkable， which can fully guarantee the efficiency and improve the therapeutic time index， so as to optimize the clinical condition of severe pneumonia and to optimize their quality of life. 　　[Key words] Imipenem； Cilastatin sodium； Severe pneumonia 　　?多重症感染项目中，重症肺炎作为其中之一，影响较为严重，其主要于患者的肺部表现，并且发展速度极为迅速，此类患者往往并发呈现出全身炎症反应综合征的情况、脓毒血症的情况以及多器官功能衰竭的情况，对于此类并发症均存在较为严重的致死性。对于重症肺炎患者临床主要以全身中毒症状以及持续性高热症状为典型，从而较易呈现出致死性的情况[1]。对于重症肺炎患者而言，其最终的死亡率